Cancer research
Developing Predictive Models for Breast Cancer Using Clinical Trial Data Sharing Platforms
Researchers have developed a tumor growth inhibition- overall survival (TGI-OS) model for hormone receptor-positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer using clinical trial data available through Vivli, a clinical trial data sharing platform. The TGI-OS model, a parametric model linking TGI metrics and baseline predictors